Cost-Effectiveness of Sacituzumab Govitecan Versus Chemotherapy in Metastatic Triple—Negative Breast Cancer in Taiwan
From the NHIA perspective, SG is not cost-effective for patients with advanced or metastatic TNBC at its current price. Substantial price reductions would be required for SG to become cost-effective under the WTP threshold of USD 102,120 per QALY.
Authors
- Shyh-Yau Wang
- Suet Yi Leung (ORCID: https://orcid.org/0000-0001-8614-4619)
- Yun-Sheng Tai
- Agnes L. F. Chan
- Henry W. C. Leung
Institutions
- China Medical University (TW)
- An-Nan Hospital (TW)
- Chia Nan University of Pharmacy and Science (TW)
Publication Details
- Journal
- Cancers
- Published
- 2025-10-13
- DOI
- https://doi.org/10.3390/cancers17203305
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- China Medical University
- Tainan Municipal An-Nan Hospital